Clinical Trial Update: CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial combining crizotinib and sunitinib for metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sutent (sunitinib)
• Xalkori (crizotinib)

Snippet

Sponsor: Mothaffar Rimawi | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED